{Reference Type}: Case Reports
{Title}: The potential role of assisted oocyte activation in the management of a POSEIDON group 3 patient with fertilization failure: A case report and literature review.
{Author}: Tsai TC;Chiung HK;Chen LH;Wu HM;
{Journal}: Taiwan J Obstet Gynecol
{Volume}: 60
{Issue}: 3
{Year}: May 2021
{Factor}: 1.944
{DOI}: 10.1016/j.tjog.2021.03.034
{Abstract}: <B>OBJECTIVE: </B>Assisted oocyte activation combined with ICSI (ICSI-AOA) has been reported to improve fertilization outcomes of couples with oocyte activation deficiency (OAD). Although there's no sufficient evidence to support ICSI-AOA as routine use, it might be beneficial for POSEIDON group 3 patients with suspected oocyte-related OAD.<BR><B>METHODS: </B>A 29-year-old female presented with a history of primary infertility for two years. She was classified as a POSEIDON group 3 patient and had a total fertilization failure history. With the help of ICSI-AOA, six oocytes were successfully fertilized. Pregnancy was later confirmed after embryo transfer. A living infant was born after 34 weeks of pregnancy.<BR><B>CONCLUSIONS: </B>OAD should be taken into consideration for POSEIDON group 3 patients since low Antimüllerian hormone is associated decreased quality. Further research needs to be done to understand the mechanism underlying oocyte-related OAD and the potential role of ICSI-AOA in young patients with suboptimal ovarian response.